Apr 30, 2024
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
Read more
Apr 30, 2024
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Read more
Apr 25, 2024
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Read more
Apr 15, 2024
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Read more
Apr 12, 2024
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Read more
Apr 12, 2024
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Read more
Displaying 1 - 10 of 20